Unique Stroma of Higher-Grade Pancreatic Intraepithelial Neoplasia: Fibroblastic Cluster Formation and CD36 Downregulation.

IF 1.9 3区 医学 Q3 ONCOLOGY
Oncology Pub Date : 2026-07-14 DOI:10.1159/000553573
Yuuji Aoki, Yuki Fukumura, Jun Nakahodo, Yoshihiro Mezawa, Yifare Maimaitiaili, Mulading Maimaitituerxun, Takashi Yao
{"title":"Unique Stroma of Higher-Grade Pancreatic Intraepithelial Neoplasia: Fibroblastic Cluster Formation and CD36 Downregulation.","authors":"Yuuji Aoki, Yuki Fukumura, Jun Nakahodo, Yoshihiro Mezawa, Yifare Maimaitiaili, Mulading Maimaitituerxun, Takashi Yao","doi":"10.1159/000553573","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Identifying pathological markers to differentiate between high- and low-grade pancreatic intraepithelial neoplasia (PanIN) remains an unmet clinical need. Recent studies suggest that the tumor microenvironment undergoes dynamic changes during PanIN progression. To establish objective pathological markers, this study investigated histological, immunohistochemical, and molecular alterations in PanIN-associated stroma across different grades.</p><p><strong>Methods: </strong>Fibroblastic cluster (FC) was defined and characterized using immunohistochemistry (IHC) for SMA, CD31, and CD34, and their frequency was assessed according to PanIN grade in 202 PanIN lesions and 58 normal ducts. To identify molecular differences among PanIN types, multiple gene expression analysis (MGEA) was performed for six normal ducts and for three PanIN1, three PanIN2, and six PanIN3 lesions. IHC and fluorescent dual IHC for CD31 and CD36 were performed to quantify CD36-positive stromal vessels. RNA scope for PPARγ and IHC for thrombospondin-1 (TSP-1) and forkhead box O1 (FOXO-1) were performed to explore the molecular basis of CD36 downregulation.</p><p><strong>Results: </strong>FCs were identified in 86.6% of PanIN3 stroma and were significantly more frequent than in lower-grade PanINs. MGEA revealed downregulation of CD36 in PanIN2-3 compared with PanIN1, and CD36-positive vessels were significantly fewer in higher-grade PanIN stroma. PPARγ signals were present in low-grade but absent in high-grade PanIN stroma. TSP-1 expression paralleled CD36 expression. These findings suggest that the possible relationship between the repression of CD36 in the stromal vasculature of high-grade PanIN and reduced PPARγ and TSP-1 signaling.</p><p><strong>Conclusions: </strong>Higher-grade PanINs harbor a unique stroma characterized by FC formation and an increased proportion of CD36-negative vessels.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-12"},"PeriodicalIF":1.9000,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13480974/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000553573","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Identifying pathological markers to differentiate between high- and low-grade pancreatic intraepithelial neoplasia (PanIN) remains an unmet clinical need. Recent studies suggest that the tumor microenvironment undergoes dynamic changes during PanIN progression. To establish objective pathological markers, this study investigated histological, immunohistochemical, and molecular alterations in PanIN-associated stroma across different grades.

Methods: Fibroblastic cluster (FC) was defined and characterized using immunohistochemistry (IHC) for SMA, CD31, and CD34, and their frequency was assessed according to PanIN grade in 202 PanIN lesions and 58 normal ducts. To identify molecular differences among PanIN types, multiple gene expression analysis (MGEA) was performed for six normal ducts and for three PanIN1, three PanIN2, and six PanIN3 lesions. IHC and fluorescent dual IHC for CD31 and CD36 were performed to quantify CD36-positive stromal vessels. RNA scope for PPARγ and IHC for thrombospondin-1 (TSP-1) and forkhead box O1 (FOXO-1) were performed to explore the molecular basis of CD36 downregulation.

Results: FCs were identified in 86.6% of PanIN3 stroma and were significantly more frequent than in lower-grade PanINs. MGEA revealed downregulation of CD36 in PanIN2-3 compared with PanIN1, and CD36-positive vessels were significantly fewer in higher-grade PanIN stroma. PPARγ signals were present in low-grade but absent in high-grade PanIN stroma. TSP-1 expression paralleled CD36 expression. These findings suggest that the possible relationship between the repression of CD36 in the stromal vasculature of high-grade PanIN and reduced PPARγ and TSP-1 signaling.

Conclusions: Higher-grade PanINs harbor a unique stroma characterized by FC formation and an increased proportion of CD36-negative vessels.

高级别胰腺上皮内瘤的独特基质:成纤维细胞簇形成和cd36下调。
通过病理标记来区分高级别和低级别胰腺上皮内瘤变(PanIN)仍然是一个未满足的临床需求。最近的研究表明,肿瘤微环境在PanIN进展过程中发生了动态变化。为了建立客观的病理标记,本研究研究了不同级别panin相关基质的组织学、免疫组织化学和分子变化。方法:采用免疫组化(IHC)方法对SMA、CD31和CD34的纤维母细胞簇(FC)进行定义和表征,并根据202例PanIN病变和58例正常导管的PanIN分级评估其出现频率。为了确定PanIN类型之间的分子差异,我们对6个正常导管、3个PanIN1、3个PanIN2和6个PanIN3病变进行了多基因表达分析(MGEA)。对CD31和CD36进行免疫组化和荧光双免疫组化,定量CD36阳性基质血管。通过RNA范围检测PPAR,IHC检测血小板反应蛋白1 (TSP-1)和叉头盒1 (FOXO-1),探索CD36下调的分子基础。结果:FCs在86.6%的PanIN3间质中被发现,明显高于低级别PanIN3间质。与PanIN1相比,MGEA显示PanIN2-3中CD36表达下调,高分级PanIN间质中CD36阳性血管明显减少。PPAR信号在低级别PanIN间质中存在,而在高级别PanIN间质中不存在。TSP-1表达与CD36表达平行。这些发现提示高级别PanIN间质血管中CD36的抑制与PPAR和TSP-1信号的减少之间可能存在关系。结论:高级别PanINs具有以FC形成和cd36阴性血管比例增加为特征的独特基质。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncology
Oncology 医学-肿瘤学
CiteScore
6.00
自引率
2.90%
发文量
76
审稿时长
6-12 weeks
期刊介绍: Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书